299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02819856 (ClinicalTrials.gov)	July 21, 2017	16/6/2016	SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity	Ototoxicity	Drug: Placebo;Drug: SPI-1005 Ebselen 200mg Capsule x1;Drug: SPI-1005 Ebselen 200mg Capsule x2;Drug: SPI-1005 Ebselen 200mg Capsule x3	Sound Pharmaceuticals, Incorporated	Medical University of South Carolina;Cystic Fibrosis Foundation	Enrolling by invitation	18 Years	N/A	All	80	Phase 2	United States
2	NCT00153634 (ClinicalTrials.gov)	March 2004	8/9/2005	Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)	Standard vs. Biofilm Susceptibility Testing in CF	Cystic Fibrosis;Chronic Bronchitis	Drug: IV amikacin;Drug: PO azithromycin;Drug: IV ceftazidime;Drug: PO ciprofloxacin;Drug: IV meropenem;Drug: IV piperacillin-tazobactam;Drug: IV ticarcillin-clavulanate;Drug: IV tobramycin	Seattle Children's Hospital	Cystic Fibrosis Foundation Therapeutics	Completed	14 Years	N/A	Both	75	N/A	United States